Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study

Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy

(2011) Jean-Claude Tardif et al.   EUROPEAN HEART JOURNAL

Heart rate reduction with ivabradine prevents the global phenotype of left ventricular remodeling

(2010) Claudio Ceconi et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Heart rate reduction in cardiovascular disease and therapy

(2010) Jan-Christian Reil et al.   Clinical Research in Cardiology

Vascular Pathophysiology in Response to Increased Heart Rate

(2010) Florian Custodis et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study

(2010) Karl Swedberg et al.   LANCET

Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial

(2010) Michael Böhm et al.   LANCET

Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the IfInhibitor Ivabradine Trial (SHIFT)

(2009) Karl Swedberg et al.   EUROPEAN JOURNAL OF HEART FAILURE

Heart Rate Reduction by If-Channel Inhibition and its Potential Role in Heart Failure with Reduced and Preserved Ejection Fraction

(2009) Jan-Christian Reil et al.   TRENDS IN CARDIOVASCULAR MEDICINE

Heart Rate Reduction by Ivabradine Reduces Oxidative Stress, Improves Endothelial Function, and Prevents Atherosclerosis in Apolipoprotein E–Deficient Mice

(2008) Florian Custodis et al.   CIRCULATION